RAM
HAE icon

Riggs Asset Management’s Haemonetics HAE Stock Holding History

Riggs Asset Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5
Closed -$383 – 668
2024
Q4 		$383 Hold
5
– – ﹤0.01% 591
2024
Q3 		$402 Hold
5
– – ﹤0.01% 571
2024
Q2 		$414 Hold
5
– – ﹤0.01% 569
2024
Q1 		$427 Buy
+5
New +$392 ﹤0.01% 556

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Riggs Asset Management's HAE Position: Q1 2025 in Review

Riggs Asset Management sold out of Haemonetics (HAE) in Q1 2025, closing a stake of 5 shares — an estimated $383 sold.

Riggs Asset Management first reported a position in HAE in Q1 2024 and held it in 4 quarters. The position peaked at $427 in Q1 2024. 314 funds tracked by Wall St. Rank hold HAE as of Q1 2025.

  • Riggs Asset Management reported no remaining Haemonetics position as of Q1 2025 after selling out during the quarter.
  • Riggs Asset Management sold 5 Haemonetics shares in Q1 2025, an estimated $383.
  • Riggs Asset Management first reported a position in Haemonetics in Q1 2024 and held it in 4 quarters.
  • Riggs Asset Management's Haemonetics position peaked at $427 in Q1 2024.
  • 314 funds tracked by Wall St. Rank held Haemonetics as of Q1 2025.

Based on Riggs Asset Management's 13F filing for Q1 2025, filed 29 Apr 2025.